Sugi Predict

Sugi Predict / Compounds / SCHEMBL648673

SCHEMBL648673

SCHEMBL648673

Cc1cccc(OCc2ccccc2)c1N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.65
▸ L3MBTL1 Q9Y468 2/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ TDP1 Q9NUW8 1/20 0.65
▸ HTR1A P08908 3/20 0.54
▸ ADRA1D P25100 2/20 0.54
▸ ADRA1A P35348 2/20 0.54
▸ ADRA1B P35368 2/20 0.54
▸ LTA4H P09960 1/20 0.53
▸ MAPK14 Q16539 1/20 0.53
▸ RXRA P19793 1/20 0.51
▸ RXRB P28702 1/20 0.51
▸ RXRG P48443 1/20 0.51
▸ LIPE Q05469 1/20 0.50
▸ SGMS2 Q8NHU3 2/20 0.48
▸ ATP4A P20648 1/20 0.48
▸ ATP4B P51164 1/20 0.48
▸ DCPS Q96C86 1/20 0.48
▸ DRD2 P14416 1/20 0.47
▸ KDM1A O60341 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11828242 0.87 MAPT (0.64) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL10411491 0.86 MAPT (0.55) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL265584 0.83 MAPK1 (0.70) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL29874217 0.83 MAPK1 (0.70) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL3489533 0.81 MAPT (0.58) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL2880443 0.81 MAPT (0.81) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL30735848 0.81 MAPT (0.62) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL30719053 0.81 MAPT (0.62) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL6351911 0.81 MAPT (0.62) MAPTL3MBTL1MAPK1TDP1HTR1A
SCHEMBL19612388 0.80 L3MBTL1 (0.67) MAPTL3MBTL1MAPK1TDP1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 — — US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 — — WO disclosed
EP-1963294-B1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2012-10-10 — — EP disclosed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 — — US disclosed
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-7834007-B2 CGRP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-16 — — US disclosed
US-7834007-B2 CGRP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-16 — — US disclosed
CN-101160128-B Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient UBE INDUSTRIES 2010-08-18 — — CN disclosed
CN-1863779-B indazole derivatives UBE INDUSTRIES 2010-05-05 — — CN disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 — — US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 — — EP disclosed
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) NOVARTIS AG (CH) 2008-11-27 — — US disclosed
EP-1963294-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) Novartis AG (CH) 2008-09-03 — — EP disclosed
CN-101160128-A Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient UBE INDUSTRIES (JP) 2008-04-09 — — CN disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
WO-2007067613-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2007-06-14 — — WO disclosed
US-20070049577-A1 CGRP antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-03-01 — — US disclosed
US-20070049577-A1 CGRP antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-03-01 — — US disclosed
CN-1863779-A Novel indazole derivative UBE INDUSTRIES (JP) 2006-11-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) PTPRS, PTPN5, PTPRR MAPT 3152/4885L3MBTL1 2780/4885MAPK1 646/4885
US-20070049577-A1 CGRP antagonists CALCRL, CALCR, CALCA MAPT 1905/4885L3MBTL1 4763/4885MAPK1 1174/4885
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC MAPT 3315/4885L3MBTL1 2493/4885MAPK1 624/4885
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 MAPT 1495/4885L3MBTL1 4251/4885MAPK1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.